Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Next Previous
X
Search
Trial Profile

Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

    • Most Recent Events

    • 27 Apr 2020 Results published in the Neurology
    • 12 Jun 2019 Primary endpoint (Change in wake after sleep onset (WASO) from baseline to Days 1 and 2) has been met, according to results presented in an Idorsia Pharmaceuticals media release.
    • 12 Jun 2019 According to an Idorsia Pharmaceuticals media release, results assessing the efficacy and safety of ACT-541468 in elderly patients with insomnia disorder were presented at SLEEP 2019 (in San Antonio, Texas, USA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top